US FDA drug approvals in oncology: the latest news
In our ongoing roundup article, we cover the latest oncology drugs being approved by the US FDA. Read on to discover what new therapeutic options are emerging for a range of cancer types. Anktiva® (N-803) Approved: April 22 2024 Indication: Non-muscle-invasive bladder cancer ANKTIVA (a first-in-class IL-15 agonist immunotherapy), plus BCG has received Breakthrough Therapy Designation and approval from the FDA in late April for BCG-unresponsive non-muscle invasive bladder cancer. "ANKTIVA not only proliferates and activates the patient’s own NK cells and CD8+ killer T cells, but also activates CD4+ T helper cells, thus enhancing the proliferation of memory killer...
